Oura Shelves Its $2.2 Billion IPO as Market Uncertainty Spoils the Fall Window

Oura is postponing its planned $2.2 billion Nasdaq initial public offering despite strong demand, the Finnish smart-ring maker said Tuesday, blaming ‘uncertainty in the IPO market’ — turning the fall season’s most-watched debut into a cautionary tale about the listing window itself.

The deal that almost priced Tuesday

The offering was lined up to price after Tuesday’s close: 50 million shares at an indicated $40 to $44 apiece, worth up to $2.2 billion, with the company itself selling just 13.5 million of those shares and existing investors selling the other 36.5 million — about 73% of the deal. At the top of the range, Oura would have carried a fully diluted valuation of $15.62 billion, up from roughly $11 billion in last year’s private round. The book, according to Bloomberg reporting summarized by ZeroHedge, was nearly four times subscribed. That is what makes the timing sting: the demand was real, and the company walked away anyway.

Five banks sat at the top of the prospectus — Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co. and Jefferies — above an 18-bank syndicate that ran from BofA and Barclays down to Robinhood and Coinbase at the retail end. Eli Lilly and Dragoneer Investment Group had signaled $400 million of cornerstone interest, about 19% of the deal. And the calendar math was impossible to ignore: Oura’s debut would have been the first U.S. offering to raise more than $1 billion since Jersey Mike’s in July.

Profitable, growing, and shelving it anyway

None of this is a company story — the release says so plainly. ‘Oura is profitable, growing meaningfully, and the business has further strengthened since beginning the IPO process.’ Consumer response to Oura Ring 5, introduced in June at $400 to $500, has been ‘exceptionally strong,’ pushing paid members to 5.7 million from 5.0 million at the end of June. For fiscal 2026 the company expects revenue to grow 90% year over year. Chief executive Tom Hale’s is the line bankers will quote: ‘We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment. In the meantime, we will execute against the opportunities ahead.’

Analysts had marked this one as the season’s bellwether: Reuters noted the offering would have been the first sizable fall-window U.S. IPO since the summer lull, ‘a key test of investor appetite for high-growth companies.’ It is the window that failed the test, not the candidate.

The $924 million asterisk on the profit story

‘Profitable’ deserves a careful look. For the nine months through June 30, Oura reported $1.21 billion in revenue, up 74% from $697.6 million a year earlier, and net income of $60.8 million, against $1.6 million in the same period last year — the operating bottom line, and genuinely profitable. But the line that belongs to common shareholders reads very differently: a net loss of $924.3 million, against $182.8 million a year earlier.

Both numbers are real. The gap is a $985.0 million deemed dividend to preferred holders, an accounting entry created when Oura spent about $1.17 billion buying back preferred stock ahead of the IPO — the repurchased shares were carried on the books at just $108.3 million, so the excess is charged against the common-stock line. It is capital-structure accounting, not cash out the door: operating cash flow was $328.0 million, pro forma diluted earnings were $0.18 a share, and cash earnings — pretax earnings minus noncash charges — were $107 million. The honest read: GAAP-profitable on net income, with a common-stockholder loss built from the pre-IPO buyback.

A widening pile of shelved debuts

Oura is joining a widening pile of shelved debuts. Nuclear-services firm Holtec Nuclear suspended its U.S. offering earlier this month amid scrutiny of the capital being deployed into artificial-intelligence-linked sectors; CVC-backed Bamboo Insurance followed. Anthropic pushed its own blockbuster from October to November, with investors expecting a valuation north of $2 trillion and a raise of up to $100 billion — figures that would eclipse SpaceX’s June debut records. None of the postponers are claiming weak demand. The problem is the weather.

The weather is measurable. U.S. listings have raised $127 billion so far this year — up 400% from 2025 — yet the appetite for new paper has thinned as investors question whether the AI trade has run its course, digest the Federal Reserve’s rate hike and the prospect of another in late October, and watch volatile oil prices, driven by disruptions to flows through the Strait of Hormuz, feed back into inflation expectations. The 10-year Treasury sits around 5.2%; Brent crude is near $107. Newly listed companies, which lack a public track record, are the first casualties when risk appetite turns.

What a second try looks like

The mechanics of a reboot are straightforward. The registration statement Oura filed with the U.S. securities regulator has not been declared effective, so no shares were sold and no new filing is needed to try again when conditions improve. The disclosed cornerstones — Lilly and Dragoneer — show where the anchor demand sits. And the valuation math is now a matter of public record, methodology labeled: $15.62 billion fully diluted at the top of the range per Reuters, $14.9 billion fully diluted at the midpoint per Renaissance Capital, $13.5 billion at the midpoint on a market-cap basis per Barron’s.

The subscription engine is what the company is really selling: 5.7 million paid members, 85% twelve-month retention, hardware at roughly 80% of nine-month revenue with $240.5 million from membership subscriptions, and a customer base Barron’s notes is more than 70% women — an unusual skew in consumer hardware. The half-billion dollars Oura itself would have netted was earmarked almost entirely to cover withholding taxes on employee stock options; the rest of the $2.2 billion would have gone to the selling investors, led by Forerunner Ventures and Lifeline Ventures.